Organogenesis (NASDAQ:ORGO - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Organogenesis to post earnings of ($0.02) per share for the quarter. Organogenesis has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company's conference call can do so using this link.
Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.11). The company had revenue of $130.23 million for the quarter, compared to analyst estimates of $122.48 million. Organogenesis had a negative net margin of 3.69% and a negative return on equity of 6.03%. On average, analysts expect Organogenesis to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Organogenesis Price Performance
NASDAQ:ORGO traded up $0.05 during trading hours on Tuesday, reaching $3.04. 224,382 shares of the company's stock were exchanged, compared to its average volume of 821,192. The company has a quick ratio of 2.42, a current ratio of 2.73 and a debt-to-equity ratio of 0.22. Organogenesis has a 12 month low of $1.96 and a 12 month high of $4.70. The business's 50-day simple moving average is $2.88 and its two-hundred day simple moving average is $2.77. The company has a market capitalization of $403.01 million, a P/E ratio of -23.00 and a beta of 1.60.
Organogenesis Company Profile
(
Get Free Report)
Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.
Featured Stories
Before you consider Organogenesis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.
While Organogenesis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
